Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis
- PMID: 18185500
- PMCID: PMC3799954
- DOI: 10.1038/sj.npp.1301643
Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis
Abstract
Cannabis is one of the most widely used illicit substances and there is growing interest in the association between cannabis use and psychosis. Delta-9-Tetrahydrocannabinol (Delta-9-THC) the principal active ingredient of cannabis has been shown to induce psychotomimetic and amnestic effects in healthy individuals. Whether people who frequently use cannabis are either protected from or are tolerant to these effects of Delta-9-THC has not been established. In a 3-day, double-blind, randomized, placebo-controlled study, the dose-related effects of 0, 2.5, and 5 mg intravenous Delta-9-THC were studied in 30 frequent users of cannabis and compared to 22 healthy controls. Delta-9-THC (1) produced transient psychotomimetic effects and perceptual alterations; (2) impaired memory and attention; (3) increased subjective effects of 'high'; (4) produced tachycardia; and (5) increased serum cortisol in both groups. However, relative to controls, frequent users showed blunted responses to the psychotomimetic, perceptual altering, cognitive impairing, anxiogenic, and cortisol increasing effects of Delta-9-THC but not to its euphoric effects. Frequent users also had lower prolactin levels. These data suggest that frequent users of cannabis are either inherently blunted in their response to, and/or develop tolerance to the psychotomimetic, perceptual altering, amnestic, endocrine, and other effects of cannabinoids.
Figures




Similar articles
-
The effects of cannabinoids on serum cortisol and prolactin in humans.Psychopharmacology (Berl). 2009 May;203(4):737-44. doi: 10.1007/s00213-008-1422-2. Epub 2008 Dec 16. Psychopharmacology (Berl). 2009. PMID: 19083209 Free PMC article.
-
Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.Int J Neuropsychopharmacol. 2020 Dec 3;23(9):559-570. doi: 10.1093/ijnp/pyaa031. Int J Neuropsychopharmacol. 2020. PMID: 32385508 Free PMC article.
-
Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans.Psychopharmacology (Berl). 2008 Jul;198(4):587-603. doi: 10.1007/s00213-007-1042-2. Epub 2008 Jan 29. Psychopharmacology (Berl). 2008. PMID: 18228005 Free PMC article.
-
Cannabis-associated psychosis: Neural substrate and clinical impact.Neuropharmacology. 2017 Sep 15;124:89-104. doi: 10.1016/j.neuropharm.2017.06.018. Epub 2017 Jun 17. Neuropharmacology. 2017. PMID: 28634109 Review.
-
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.Lancet Psychiatry. 2020 Apr;7(4):344-353. doi: 10.1016/S2215-0366(20)30074-2. Epub 2020 Mar 17. Lancet Psychiatry. 2020. PMID: 32197092 Free PMC article.
Cited by
-
Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans.Psychopharmacology (Berl). 2013 Apr;226(3):515-29. doi: 10.1007/s00213-012-2924-5. Epub 2012 Dec 9. Psychopharmacology (Berl). 2013. PMID: 23224510 Free PMC article. Clinical Trial.
-
Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.Transl Psychiatry. 2022 Sep 6;12(1):369. doi: 10.1038/s41398-022-02112-8. Transl Psychiatry. 2022. PMID: 36068202 Free PMC article.
-
Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways.Br J Pharmacol. 2011 Jan;162(1):286-94. doi: 10.1111/j.1476-5381.2010.01015.x. Br J Pharmacol. 2011. PMID: 20825410 Free PMC article.
-
The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans.Pharmacol Biochem Behav. 2011 Mar;98(1):94-100. doi: 10.1016/j.pbb.2010.12.013. Epub 2010 Dec 21. Pharmacol Biochem Behav. 2011. PMID: 21176784 Free PMC article. Clinical Trial.
-
The Impact of THC and CBD in Schizophrenia: A Systematic Review.Front Psychiatry. 2021 Jul 23;12:694394. doi: 10.3389/fpsyt.2021.694394. eCollection 2021. Front Psychiatry. 2021. PMID: 34366924 Free PMC article.
References
-
- Anthony JC, Trinkoff AM. United States epidemiologic data on drug use and abuse: how are they relevant to testing abuse liability of drugs? NIDA Res Monogr. 1989;92:241–66. - PubMed
-
- Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metabolism & Disposition. 1995;23:825–31. - PubMed
-
- Brandt J. The Hopkins Verbal Learning Test. Development of a New Memory Test with 6 Equivalent Forms. The Clinical Neuropsychologist. 1991;5:125–142.
-
- Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem. 1999;73:2447–59. - PubMed
-
- Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) Journal of Traumatic Stress. 1998;11:125–36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical